Testing VC005 cream for mild-to-moderate eczema in teens and adults
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old
- You have been diagnosed with atopic dermatitis (eczema) using standard medical criteria
- Your eczema has been stable for at least 2 weeks (not suddenly improving or worsening)
- Your eczema affects areas beyond just your hands or feet—such as your face, neck, or inner elbows
- You don't have other skin conditions (like psoriasis, acne, or skin cancer) in the areas being treated
- Your skin doesn't have large scars, tattoos, or significant pigmentation changes where the study medication would be applied
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
This study tests a new ointment (HL-300) designed to treat mild-to-moderate atopic dermatitis (a chronic skin condition causing itching and inflammation). You would apply it to affected skin areas to see if it safely reduces symptoms.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This study tests a new moisturizing product (RV4421B) for people with mild to moderate atopic dermatitis (eczema). Participants will use the product along with their usual steroid cream for 12 weeks to see how well it works and if it’s safe for different ages, from babies to adults.
This trial tests a new gel called PG-011 for people with mild to moderate eczema (atopic dermatitis). The gel is applied to the skin, and the study will check if it helps improve symptoms safely.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.